Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Comment by microcapon Apr 13, 2022 11:32pm
151 Views
Post# 34602664

RE:RE:RE:share buyback

RE:RE:RE:share buybackThey were a few small sales by Wilson and Raghubir around the time of the annual share grant (RSUs). Hardly cause for concern.

The three discontinued products totaled less than $2M in revenue in 2021. Of course this headwind will reduce the growth rate in 2022, but important to keep in mind that only one was meaningfully profitable. Yes, Q4 benefited from an inventory build on those, and an unusually large Protect-It order, but was the impressive bottom line was largely reduced launch spend on Combogesic and Tibella.

I think 2022 can still be a growth year, plus operating margins returning to 30%+. Next Feramax launch coming later this year. Several international orders already. Tibella gaining traction. Early indications for Combogesic don't seem very promising but it's been a tough launch environment. Honestly my optimism for it faded when I learned it was being scheduled behind the counter. Still, the dental niche seems to be working. Overall, management must be optimistic. Several sales reps hired in Q1 plus 7 more job openings on the website (5 in sales and marketing).

prophetoffact wrote: There's been insider selling around $9.
I think the last quarter may not be representative as RX is now no longer selling some products and there was inventory building by clients ahead of the transition. Listen to the Q4 video for detail.
Next month is Q1.



<< Previous
Bullboard Posts
Next >>